Mauritania

Reimbursed Care Access

Mauritania maintains a prohibitionist national drug control regime (Loi No. 93‑37) that criminalizes production, trafficking and use of substances listed in the annexes and applies strict penalties. Traditional and novel psychedelic compounds (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑family, ibogaine, ayahuasca) are included among controlled psychotropic substances in the national framework and have no authorized medical/insured pathways outside approved research; ketamine is an important clinical anesthetic listed on the WHO Model List of Essential Medicines and is used in medical settings under standard pharmaceutical regulation, but psychedelic indications (including esketamine for depression) have no formal approved / reimbursed program in Mauritania. Key primary sources: Mauritania Loi No. 93‑37 (UNODC/Sherloc) and the WHO Model List of Essential Medicines for ketamine. [https://www.unodc.org/cld/fr/document/mrt/loi_93-37.html|UNODC Sherloc: Loi 93-37] [https://medlistapp.paho.org/en/list/11|WHO Model List of Essential Medicines].